Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer

Hepatology Research

Volumn 40, Issue 12, 2010, Pages 1168-1175

  Ikeda, Kenji ^a   Kobayashi, Masahiro ^a   Seko, Yuya ^a   Imai, Norihiro ^a   Hirakawa, Miharu ^a   Kawamura, Yusuke ^a   Sezaki, Hitomi ^a   Hosaka, Tetsuya ^a   Akuta, Norio ^a   Saitoh, Satoshi ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Arase, Yasuji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Hepatitis C; Hepatocellular carcinoma; Interferon; Prevention; Recurrence

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA INTERFERON;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CEREBROVASCULAR ACCIDENT; CHILL; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEPATIC ENCEPHALOPATHY; HEPATITIS C VIRUS; HUMAN; INSOMNIA; LEUKOPENIA; LIVER CELL CARCINOMA; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 78649854047     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00720.x     Document Type: Article

References (24)

1. Arii S, Tanaka J, Yamazoe Y et al. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 1992; 69: 913-19.
2. Ikeda K, Arase Y, Kobayashi M et al. Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis. J Gastroenterol 2003; 38: 865-76.
3. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
4. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394-402.
5. Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C - a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124- 30.
6. Ikeda K, Arase Y, Saitoh S et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-32.
7. Kubo S, Nishiguchi S, Hirohashi K et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 15: 963-7.
8. Shiratori Y, Shiina S, Teratani T et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138: 299-306.
9. Sakaguchi Y, Kudo M, Fukunaga T et al. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48: 64-70.
10. Hung CH, Lee CM, Wang JH et al. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005; 20: 1553-9.
11. Mazzaferro V, Romito R, Schiavo M et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-54.
12. Jeong SC, Aikata H, Katamura Y et al. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007; 13: 5343-50.
13. Kashiwagi K, Furusyo N, Kubo N et al. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother 2003; 9: 333-40.
14. Damdinsuren B, Nagano H, Sakon M et al. Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 2003; 10: 1184-90.
15. Matsumoto K, Okano J, Murawaki Y. Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells. J Gastroenterol 2005; 40: 722-32.
16. Murata M, Nabeshima S, Kikuchi K et al. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine 2006; 33: 121-8.
17. Damdinsuren B, Nagano H, Wada H et al. Stronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells. Int J Oncol 2007; 30: 201-8.
18. SPSS SPSS for Windows Version 11.0 Manual. SPSS, Chicago, IL, 2001.
19. Dunk AA, Ikeda T, Pignatelli M, Thomas HC. Human lymphoblastoid interferon: in vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 1986; 2: 419-29.
20. Lai CL, Lau JY, Wu PC et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17: 389-94.
21. Wang L, Wu WZ, Sun HC et al. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003; 7: 587-94.
22. Wu WZ, Sun HC, Shen YF et al. Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol 2005; 131: 169-78.
23. Moreno MG, Muriel P. Remission of liver fibrosis by interferon-alpha 2b. Biochem Pharmacol 1995; 50: 515-20.
24. Tarao K, Takemiya S, Tamai S et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997; 79: 688-94.